Cargando…
Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report
BACKGROUND: Direct-Acting agents (DAAs) target and inhibit essential viral replication proteins. They have revolutionized the treatment of Hepatitis C virus (HCV) infection reaching high levels of sustained virologic response. However, the detection of basal resistance-associated substitutions (RASs...
Autores principales: | Aldunate, Fabián, Echeverría, Natalia, Chiodi, Daniela, López, Pablo, Sánchez-Cicerón, Adriana, Soñora, Martín, Cristina, Juan, Moratorio, Gonzalo, Hernández, Nelia, Moreno, Pilar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077789/ https://www.ncbi.nlm.nih.gov/pubmed/33902462 http://dx.doi.org/10.1186/s12879-021-06080-0 |
Ejemplares similares
-
Response to: Comment on “Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients”
por: Aldunate, Fabián, et al.
Publicado: (2019) -
Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients
por: Aldunate, Fabián, et al.
Publicado: (2018) -
Evaluation of SYBR Green real time PCR for detecting SARS-CoV-2 from clinical samples
por: Pereira-Gómez, Marianoel, et al.
Publicado: (2021) -
IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients
por: Echeverría, Natalia, et al.
Publicado: (2018) -
In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?
por: Echeverría, Natalia, et al.
Publicado: (2021)